Contents
Issue 141 • April 2024
In association with
In Depth
What’s Next for AAV Gene Therapies in 2024?
Traceability technologies tighten supply chain fakery
Switching sales: Investigating the impact of FDA’s priority vouchers
Is HIV-TB coinfection treatment entering a new frontier?
Patient organisations need to tackle transparency
AD/PD 2024: Eli Lilly’s donanemab hit with FDA delay
Q&A: Awareness key for digital therapeutics to realise full potential